Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer

Dacomitinib, a second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor, is a standard therapeutic option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, its efficacy in patients with central nervous system lesions is unclear. Here, we describe a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizusaki, Shun, Otsubo, Kohei, Ninomiya, Toshifumi, Arimura, Hidenobu, Tsuchiya‐Kawano, Yuko, Inoue, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779185/
https://www.ncbi.nlm.nih.gov/pubmed/33112047
http://dx.doi.org/10.1111/1759-7714.13712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779185/
https://www.ncbi.nlm.nih.gov/pubmed/33112047
http://dx.doi.org/10.1111/1759-7714.13712

Ejemplares similares